Pancreatic cancer: this “revolutionary” tablet validated in record time by Europe causes survival to jump

Pancreatic cancer: this “revolutionary” tablet validated in record time by Europe causes survival to jump
In less than a month, between the CHMP opinion and November 17, 2026, the European Commission validated daraxonrasib against metastatic pancreatic cancer. How could this accelerated green light reshuffle the cards for the patients concerned in the European Union?

Faced with a metastatic pancreatic cancer which still wins the majority of patients in a few months, each month saved counts. In Europe, where there are around 16,000 new cases per year in France according to the National Cancer Institute, this type of tumor remains one of the deadliest, with a five-year net survival of around 8% in men and 7% in women. In this context, a new anti-cancer tablet has just obtained a European green light in an unusually short time.

This medicine, the daraxonrasibmarketed under the name Rasonquehas just been authorized by the
European Commission on November 17, 2026 to treat adults with metastatic pancreatic adenocarcinoma who have already received at least one treatment. According to the European Medicines Agency (EMA), it almost doubled median survival compared to standard chemotherapy. An unprecedented result for more than 30 years which explains why it is presented as a “revolutionary” treatment.

What the European authorization of daraxonrasib changes in concrete terms

According to the European Commission, the marketing authorization covers the daraxonrasib/Rasonque in adults whose pancreatic cancer has already spread and progressed after at least one line of systemic treatment. The medication is taken in tablet form, once a day at home, unlike standard chemotherapy which requires infusions in hospital. The EMA specifies that this authorization responds to an “unmet medical need” for a serious illness with limited options.

This authorization applies to the entire European Union, but it does not mean immediate availability in each country. The price, reimbursement and place of
Rasonque in the care strategy will still have to be discussed state by state. According to the European Commission, daraxonrasib is already the subject of joint clinical assessment between Member States, whose report is expected in December 2026, in order to shorten these national discussions.

A green light for Rasonque obtained in record time thanks to a progressive examination

On October 15, 2026, the EMA Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Rasonque. Barely a month later, the European Commission validated this recommendation. According to the Commission, the EMA delivered its positive scientific opinion in just over 100 days, instead of the usual legal deadline of 210 days, thanks to a so-called “progressive review” procedure.

In this diagram, described by the EMA as part of the project
Cancer Medicines Pathfinderlaboratory data is analyzed as it progresses, rather than in a single chunk at the end of development. The aim is to save time without lowering requirements for safety, quality and efficiency. The European Commission insists that these standards have not been modified, the shortening of deadlines based solely on the organization of the evaluation.

Daraxonrasib: unprecedented survival gains, but a targeted treatment to monitor

The international phase 3 trial RASolute-302carried out on 500 patients already treated, serves as the basis for this decision. According to the EMA, median overall survival increased to 12.4 months with Rasonque compared to 6.7 months under chemotherapy, and progression-free survival at 7.2 months compared to 3.6 months. Publication in the New England Journal of Medicinepresented at ASCO 2026, reports a survival of 13.2 months compared to 6.7 months, a difference linked to the precise moment when the data were stopped. We will also note an objective tumor response in 31.6% of patients receiving daraxonrasib, compared to 11.2% with chemotherapy, as well as longer maintenance of quality of life and more durable pain control.

THE daraxonrasib is described by the EMA as a “pan-RAS” inhibitor: it binds to cyclophilin A, then forms a complex which blocks the RAS proteins, often mutated in this type of cancer. However, it is not a “miracle drug”. The most common adverse reactions reported by the EMA are diarrhea, rash, stomatitis, nausea and vomiting, with a significant proportion of severe events in both treatment groups. Trials continue to test daraxonrasib earlier in the disease and in combination with other treatments.